Literature DB >> 33938491

Early and Sustained Elevation in Serum Pancreatic Amylase Activity: A Novel Predictor of Morbidity after Pancreatic Surgery.

Elisa Bannone1, Giovanni Marchegiani, Alberto Balduzzi, Giuseppa Procida, Pier Giuseppe Vacca, Roberto Salvia, Claudio Bassi.   

Abstract

OBJECTIVE: To characterize early postoperative serum pancreatic amylase (spAMY) trends after pancreatic resections. SUMMARY BACKGROUND DATA: A postoperative spAMY elevation is a common finding but uncertainties remain about its meaning and prognostic implications.
METHODS: Analysis of patients who consecutively underwent pancreatectomy from 2016 to 2019. spAMY activity was assessed from postoperative day (POD) 0 to 3. Different patterns of spAMY have been identified based on the spAMY standard range (10-52 U/l).
RESULTS: Three patterns were identified: (#1) spAMY values always< the lower limit of normal/within the reference range /a single increase in spAMY >upper limit of normal at any POD; (#2) Sustained increase in spAMY activity on POD 0 + 1; (#3) Sustained increase in spAMY activity including POD 1 + 2. Shifting through spAMY patterns was associated with increase morbidity (21% in #1 to 68% in #3 at POD 7; log rank < 0.001). Almost all severe complications (at least Clavien-Dindo ≥3) occurred in patients with pattern #3 (15% vs. 3% vs. 5% in #1 and #2 at POD 7, p = 0.006), without difference considering >3-times or >the spAMY normal limit (p = 0.85). POPF (9% in #1 vs. 48% in #3, p< 0.001) progressively increased across patterns. Pre-operative diabetes (OR 0.19), neoadjuvant therapy (OR 0.22), pancreatic texture (OR 8.8), duct size (OR 0.78), and final histology (OR 2.2) were independent predictors of pattern #3.
CONCLUSIONS: A sustained increase in spAMY activity including POD 1 + 2 (#3) represents an early postoperative predictor of overall and severe early morbidity. An early and dynamic evaluation of spAMY could crucially impact the subsequent clinical course with relevant prognostic implications.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33938491     DOI: 10.1097/SLA.0000000000004921

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis.

Authors:  Anna Burelli; Giampaolo Perri; Giovanni Marchegiani
Journal:  Ann Surg Oncol       Date:  2022-03-19       Impact factor: 5.344

2.  Comparison of oncologic outcomes between pancreaticoduodenectomy and total pancreatectomy for pancreatic adenocarcinoma.

Authors:  Jisheng Zhu; Zhengying Jiang; Bin Xie; Chengchao Fu; Weidong Xiao; Yong Li
Journal:  Surg Endosc       Date:  2022-07-18       Impact factor: 3.453

3.  Risk Factors and Clinical Impacts of Post-Pancreatectomy Acute Pancreatitis After Pancreaticoduodenectomy: A Single-Center Retrospective Analysis of 298 Patients Based on the ISGPS Definition and Grading System.

Authors:  Shuai Wu; Hanxue Wu; Guiping Xu; Yaling Zhao; Feng Xue; Shunbin Dong; Liang Han; Zheng Wang; Zheng Wu
Journal:  Front Surg       Date:  2022-07-04

4.  Protective peritoneal patch for arteries during pancreatoduodenectomy: good value for money.

Authors:  Anaïs Palen; Jonathan Garnier; Jean-Robert Delpero; Olivier Turrini; Jacques Ewald
Journal:  Langenbecks Arch Surg       Date:  2021-11-23       Impact factor: 2.895

Review 5.  Early detection of pancreatic cancer using DNA-based molecular approaches.

Authors:  Aatur D Singhi; Laura D Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-07       Impact factor: 46.802

Review 6.  State of the art of robotic pancreatoduodenectomy.

Authors:  Niccolò Napoli; Emanuele F Kauffmann; Fabio Vistoli; Gabriella Amorese; Ugo Boggi
Journal:  Updates Surg       Date:  2021-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.